https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/accrued-income https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/additional-allowance-recognised-in-profit-or-loss-allowance-account-for-credit-losses-of-financial-assets https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/adjustments-for-current-tax-of-prior-period https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/adjustments-for-decrease-increase-in-inventories https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/adjustments-for-decrease-increase-in-other-operating-receivables https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/adjustments-for-decrease-increase-in-trade-account-receivable https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/adjustments-for-depreciation-and-amortisation-expense https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/adjustments-for-increase-decrease-in-other-operating-payables https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/adjustments-for-increase-decrease-in-trade-account-payable https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/average-effective-tax-rate https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/average-number-of-employees https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/basic-and-diluted-earnings-loss-per-share https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/borrowings https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/cash-and-cash-equivalents https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/cash-flows-from-used-in-financing-activities https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/cash-flows-from-used-in-investing-activities https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/cash-flows-from-used-in-operating-activities https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/cash-flows-from-used-in-operations-before-changes-in-working-capital https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/changes-in-inventories-of-finished-goods-and-work-in-progress https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/comprehensive-income https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/comprehensive-income-attributable-to-noncontrolling-interests https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/comprehensive-income-attributable-to-owners-of-parent https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/cost-of-inventories-recognised-as-expense https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/cover-page-shares-outstanding https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/current-accrued-income https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/current-assets https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/current-interest-payable https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/current-liabilities https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/current-payables-on-social-security-and-taxes-other-than-income-tax https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/current-prepaid-expenses https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/current-prepayments-and-current-accrued-income https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/current-raw-materials-and-current-production-supplies https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/current-trade-receivables https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/current-value-added-tax-receivables https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/deferred-income https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/deferred-tax-asset-when-utilisation-is-dependent-on-future-taxable-profits-in-excess-of-profits-from-reversal-of-taxable-temporary-differences-and-entity-has-suffered-loss-in-jurisdiction-to-which-deferred-tax-asset-relates https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/deferred-tax-expense-arising-from-writedown-or-reversal-of-writedown-of-deferred-tax-asset https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/depreciation-amortisation-and-impairment-loss-reversal-of-impairment-loss-recognised-in-profit-or-loss https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/effect-of-exchange-rate-changes-on-cash-and-cash-equivalents https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/employee-benefits-expense https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/equity https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/equity-and-liabilities https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/equity-attributable-to-owners-of-parent https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/expense-relating-to-variable-lease-payments-not-included-in-measurement-of-lease-liabilities https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/finance-costs https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/finance-income https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/finance-income-cost https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/financial-assets https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/financial-liabilities https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/gains-losses-on-exchange-differences-on-translation-recognised-in-profit-or-loss https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/income-tax-expense https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/increase-decrease-in-cash-and-cash-equivalents-before-effect-of-exchange-rate-changes https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/intangible-assets-other-than-goodwill https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/interest-expense https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/interest-paid-classified-as-operating-activities https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/interest-received-classified-as-operating-activities https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/inventories https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/inventories-total https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/inventory-writedown-2011 https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/investments-in-subsidiaries https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/issue-of-convertible-instruments https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/issue-of-equity https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/issued-capital https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/key-management-personnel-compensation-other-longterm-benefits https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/key-management-personnel-compensation-postemployment-benefits https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/key-management-personnel-compensation-shortterm-employee-benefits https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/key-management-personnel-compensation-termination-benefits https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/lease-and-sublease-payments-recognised-as-expense https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/loans-received https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/minimum-lease-payments-payable-under-noncancellable-operating-lease https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/minimum-operating-lease-payments https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/miscellaneous-other-operating-income https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/noncontrolling-interests https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/noncurrent-assets https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/noncurrent-financial-assets https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/notes-and-debentures-issued https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/number-of-shares-outstanding https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/oci-net-of-tax-exchange-differences-on-translation https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/operating-expense https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/other-adjustments-for-noncash-items https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/other-borrowings https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/other-comprehensive-income https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/other-current-financial-assets https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/other-current-liabilities https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/other-current-receivables https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/other-employee-expense https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/other-expense-by-function https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/other-intangible-assets https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/other-operating-income-expense https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/par-value-per-share https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/payments-for-share-issue-costs https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/postemployment-benefit-expense-defined-benefit-plans https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/postemployment-benefit-expense-defined-contribution-plans https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/proceeds-from-borrowings-classified-as-financing-activities https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/proceeds-from-current-borrowings https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/proceeds-from-issue-of-ordinary-shares https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/profit-loss https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/profit-loss-attributable-to-noncontrolling-interests https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/profit-loss-attributable-to-owners-of-parent https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/profit-loss-before-tax https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/profit-loss-from https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/profit-loss-from-operating-activities https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/property-plant-and-equipment https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/purchase-of-intangible-assets-classified-as-investing-activities https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/purchase-of-property-plant-and-equipment-classified-as-investing-activities https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/raw-materials-and-consumables-used https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/repayments-of-borrowings-classified-as-financing-activities https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/repayments-of-current-borrowings https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/research-and-development https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/reserve-of-exchange-differences-on-translation https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/retained-earnings https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/revenue https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/revenue-from-rendering-of-services https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/revenue-from-royalties https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/revenue-from-sale-of-goods https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/share-issue-related-cost https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/shortterm-investments-classified-as-cash-equivalents https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/social-security-contributions https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/tax-effect-of-expense-not-deductible-in-determining-taxable-profit-tax-loss https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/tax-effect-of-revenues-exempt-from-taxation-2011 https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/total-assets https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/total-liabilities https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/trade-and-other-current-payables https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/weighted-average-shares https://stock.noler.com/us/stock/oasmia-pharmaceutical-ab/work-in-progress